ArticleNature chemical biology2010
A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans.
Article in Nature chemical biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 189 citations in OpenAlex.
- G protein regulatory network shapes magnitude and kinetics of behavioral responses in an engineered opioid receptor model.The Journal of biological chemistry · 2026Article
- Paclitaxel-induced germline DNA-damage signatures independent of mismatch repair inFrontiers in pharmacology · 2026Article
- 6-PPD induces mitochondrial dysfunction and reduces healthspan and lifespan through SKN-1 in Caenorhabditis elegans.Journal of hazardous materials · 2025Article
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- Biotransformation of Tire-Derived 6PPD and 6PPD-Q in Soil NematodeEnvironmental science & technology · 2025Article
- Studying the mechanisms of neurodegeneration:Frontiers in cellular neuroscience · 2025Review
- Behavioral and genetic analysis of the effects of the psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI) in C. elegans.PloS one · 2025Article
- Extracellular flux assay (Seahorse assay): Diverse applications in metabolic research across biological disciplines.Molecules and cells · 2024Review
- Cyprocide selectively kills nematodes via cytochrome P450 bioactivation.Nature communications · 2024Article
- Natural variation in protein kinase D modifies alcohol sensitivity inbioRxiv : the preprint server for biology · 2024Article
- Chemical Genetics inACS chemical biology · 2024Article
- Identification of a family of species-selective complex I inhibitors as potential anthelmintics.Nature communications · 2024Article
- Toxicokinetics of the Antidepressant Fluoxetine and Its Active Metabolite Norfluoxetine inEnvironmental science & technology · 2024Article
- The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.Development (Cambridge, England) · 2024Article
- Mapping resistance-associated anthelmintic interactions in the model nematode Caenorhabditis elegans.PLoS neglected tropical diseases · 2023Article
- A drug repurposing screen for whipworms informed by comparative genomics.PLoS neglected tropical diseases · 2023Article
- Article
- Unraveling effects of anti-aging drugs on C. elegans using liposomes.GeroScience · 2023Article
- Article
- A Caenorhabditis elegans model of autosomal dominant adult-onset neuronal ceroid lipofuscinosis identifies ethosuximide as a potential therapeutic.Human molecular genetics · 2023Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
Abstract
The resistance of Caenorhabditis elegans to pharmacological perturbation limits its use as a screening tool for novel small bioactive molecules. One strategy to improve the hit rate of small-molecule screens is to preselect molecules that have an increased likelihood of reaching their target in the worm. To learn which structures evade the worm's defenses, we performed the first survey of the accumulation and metabolism of over 1,000 commercially available drug-like small molecules in the worm. We discovered that fewer than 10% of these molecules accumulate to concentrations greater than 50% of that present in the worm's environment. Using our dataset, we developed a structure-based accumulation model that identifies compounds with an increased likelihood of bioavailability and bioactivity, and we describe structural features that facilitate small-molecule accumulation in the worm. Preselecting molecules that are more likely to reach a target by first applying our model to the tens of millions of commercially available compounds will undoubtedly increase the success of future small-molecule screens with C. elegans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.